GRNA - GreenLight Biosciences Holdings Stock Price, Fair Value and News
Delayed
GRNA Stock Price
View Fullscreen
GRNA RSI Chart
GRNA Valuation
GRNA Price/Sales (Trailing)
GRNA Profitability
GRNA Fundamentals
GRNA Revenue
GRNA Earnings
Breaking Down GRNA Revenue
How does GRNA drawdown profile look like?
GRNA Financial Health
GRNA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 10.3M | 0 | 0 | 0 |
| 2022 | 1.5M | 2.8M | 4.2M | 6.8M |
| 2021 | 1.7M | 1.7M | 1.6M | 1.6M |
| 2020 | 0 | 0 | 2.4M | 1.7M |
| 2019 | 0 | 0 | 0 | 3.0M |
Get all data in R, Python etc through our Historical Stock Data APIs
Tracking the Latest Insider Buys and Sells of GreenLight Biosciences Holdings
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Jul 24, 2023 | ortega-valle marta | sold | - | - | -29,798 | - |
| Jul 24, 2023 | continental grain co | sold | - | - | -6,489,240 | - |
| Jul 24, 2023 | cooney charles l | sold | -91,594 | 0.3 | -305,314 | - |
| Jul 24, 2023 | alexandria real estate equities, inc. | sold | - | - | -1,609,910 | - |
| Jul 24, 2023 | patrick deval l | sold | - | - | -172,500 | - |
| Jul 24, 2023 | ruettgers michael c | sold | - | - | -206,629 | - |
| Jul 24, 2023 | mls capital fund ii lp | sold | - | - | -5,818,580 | - |
| Jul 24, 2023 | lewis & clark ventures i, lp | sold | - | - | -557,632 | - |
| Jul 24, 2023 | lewis & clark plant sciences fund i, lp | sold | - | - | -1,816,750 | - |
| Jul 24, 2023 | furneaux capital holdco, llc | sold | - | - | -125,221 | - |
Which funds bought or sold GRNA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Feb 14, 2024 | Skaana Management L.P. | unchanged | - | - | - | -% |
| Nov 14, 2023 | Castle Creek Arbitrage, LLC | sold off | -100 | -590 | - | -% |
| Nov 14, 2023 | Ergoteles LLC | sold off | -100 | -26,501 | - | -% |
| Nov 13, 2023 | Ayrton Capital LLC | sold off | -100 | -1,995,000 | - | -% |
Are Funds Buying or Selling GRNA?
Calls
Puts
Net Call Options
No. of Funds
GreenLight Biosciences Holdings News
Latest updates
GreenLight Biosciences Holdings Earnings Report: Key Takeaways & Analysis
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | |||||||||||||
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
| Revenue | 26.4% | 3,820,000 | 3,023,000 | 1,732,000 | 1,768,000 | 257,000 | 415,000 | 362,000 | 493,000 | 325,000 | - | - | - |
| Operating Expenses | -23.5% | 32,112,000 | 41,966,000 | 37,969,000 | 53,728,000 | 37,036,000 | 34,129,000 | 27,773,000 | 26,942,000 | 21,309,000 | - | - | - |
| S&GA Expenses | 4.3% | 8,944,000 | 8,573,000 | 8,025,000 | 9,577,000 | 9,755,000 | 6,378,000 | 5,112,000 | 4,933,000 | 3,898,000 | 1,650 | 878 | - |
| EBITDA Margin | 34.5% | -14.85 | -22.68 | -24.07 | -36.12 | -67.04 | -65.28 | - | - | - | - | - | - |
| Interest Expenses | -51.6% | 1,007,000 | 2,082,000 | 738,000 | 230,000 | 1,073,000 | 1,868,000 | 348,000 | -108,000 | 311,000 | - | - | - |
| Income Taxes | - | - | - | 1,092,000 | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 100.0% | - | -38,764,000 | -37,066,000 | - | - | - | -29,181,000 | - | 1,042,799 | - | - | - |
| EBT Margin | 34.4% | -16.05 | -24.48 | -26.92 | -40.08 | -73.55 | -70.41 | - | - | - | - | - | - |
| Net Income | 26.6% | -28,469,000 | -38,764,000 | -38,158,000 | -51,926,000 | -38,207,000 | -34,672,000 | -29,181,000 | -27,174,000 | -21,283,000 | -1,650 | -878 | - |
| Net Income Margin | 38.3% | -15.21 | -24.64 | -39.06 | -54.96 | -84.63 | -70.41 | -59.49 | -36.90 | -32.30 | -30.48 | -13.90 | -9.55 |
| Free Cashflow | -15.9% | -32,668,000 | -28,192,000 | -50,051,000 | -35,248,000 | -49,787,000 | -28,377,000 | -29,517,000 | -23,040,000 | -26,046,000 | -19,173,000 | - | - |
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | |||||||||||
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
| Assets | -23.5% | 114 | 149 | 151 | 99.00 | 122 | 63.00 | 63.00 | 208 | 208 | 114 | 31.00 |
| Current Assets | -47.1% | 38.00 | 71.00 | 109 | 64.00 | 97.00 | 34.00 | 38.00 | 1.00 | 1.00 | 97.00 | 26.00 |
| Cash Equivalents | -52.5% | 32.00 | 68.00 | 98.00 | 44.00 | 83.00 | 32.00 | 35.00 | 52.00 | 72.00 | 95.00 | 26.00 |
| Net PPE | -2.2% | 40.00 | 41.00 | 39.00 | 32.00 | 23.00 | 23.00 | 22.00 | - | - | 16.00 | 4.00 |
| Liabilities | -8.7% | 92.00 | 101 | 67.00 | 85.00 | 59.00 | 93.00 | 59.00 | 16.00 | 13.00 | 34.00 | 7.00 |
| Current Liabilities | -12.3% | 31.00 | 36.00 | 32.00 | 55.00 | 30.00 | 62.00 | 42.00 | 1.00 | 1.00 | 14.00 | 6.00 |
| Shareholder's Equity | -54.4% | 22.00 | 48.00 | 84.00 | 14.00 | 64.00 | - | 4.00 | 32.00 | 59.00 | 80.00 | 24.00 |
| Retained Earnings | -6.8% | -449 | -420 | -381 | -343 | -291 | -253 | -218 | -1.98 | 1.00 | -141 | -88.01 |
| Additional Paid-In Capital | 0.5% | 471 | 469 | 466 | 357 | 356 | 224 | 4.00 | 7.00 | 4.00 | 221 | 1.00 |
| Shares Outstanding | 0.1% | 152 | 152 | 151 | 124 | 114 | 97.00 | 96.00 | 96.00 | 96.00 | 96.00 | - |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | ||||||||||||
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
| Cashflow From Operations | -26.5% | -31,100 | -24,589 | -39,977 | -22,654 | -49,511 | -24,559 | -24,941 | -20,900 | -21,400 | - | - | - |
| Share Based Compensation | -0.4% | 2,308 | 2,318 | 2,700 | 1,634 | 2,187 | 699 | 537 | 407 | 348 | - | - | - |
| Cashflow From Investing | 55.4% | -1,608 | -3,603 | -10,074 | -12,583 | -250 | -3,677 | -4,576 | -2,098 | -4,688 | - | - | - |
| Cashflow From Financing | -44.8% | -2,989 | -2,064 | 104,272 | -3,854 | 102,497 | 25,155 | 11,931 | 3,811 | 2,634 | 132 | 25.00 | - |